Bristol-Myers Squibb CompanyBMY
NYSE • Healthcare
$58.62
P/E
16.94
PEG
—
FCF Yield
—
Rev Growth YoY
-22.0% YoY
Gross Margin
7263.0%
Health Score
4/10
D/E Ratio
2.44
Confidence
LOW
Business Snapshot
Bristol-Myers Squibb (BMY) is a large-cap global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines across oncology, hematology, immunology, and cardiovascular disease. The company competes in the highly competitive drug manufacturers segment of the healthcare sector. With a current price of $58.62 and a Price/Sales ratio of 2.49x, BMY operates at significant scale, though its market capitalisation figure is unavailable from the current data payload.
Financial Health
Score: 4/10 BMY carries a meaningful debt burden with a Debt/Equity ratio of 2.44x, signalling high financial leverage that limits balance sheet flexibility. Gross and net margin figures appear anomalously elevated in the data (gross margin of 7,263% and net margin of 1,464%), which are likely the result of data normalisation artefacts rather than reflective of true operational performance, and should be treated with caution...
Risk Assessment
- **REVENUE DECLINE:** Revenue contracted -22.0% year-over-year, indicating significant top-line deterioration that may reflect patent expirations or competitive pressure. - **HIGH LEVERAGE:** Debt/Equity of 2.44x represents a highly leveraged balance sheet, limiting financial flexibility in a rising-cost or revenue-stress environment. - **FREE CASH FLOW ABSENT:** FCF data is unavailable, making it impossible to assess debt serviceability or capital return sustainability. - **TECHNICAL DETERIORATION:** A confirmed death cross (50-day MA crossing below 200-day MA) with price trading below both moving averages signals sustained negative price momentum. - **DATA QUALITY:** Margin figures (gross margin 7,263%; net margin 1,464%) are anomalous and likely reflect data distortions, undermining confidence in reported profitability metrics....